Advances in ophthalmology practice and research最新文献

{"title":"Risk factors for intraoperative floppy iris syndrome in female cataract patients: The roles of ARB medication and diabetes mellitus","authors":"Yiwei Wu ,&nbsp;Lipu Cui ,&nbsp;Yongyuan He ,&nbsp;Peiyao Jin ,&nbsp;Yuyu Miao ,&nbsp;Yingyan Ma ,&nbsp;Qian Sun ,&nbsp;Bijun Zhu ,&nbsp;Baojiang Li ,&nbsp;Ying Zheng ,&nbsp;Qi Yu ,&nbsp;Huiyi Jin ,&nbsp;Haidong Zou","doi":"10.1016/j.aopr.2025.12.004","DOIUrl":"10.1016/j.aopr.2025.12.004","url":null,"abstract":"<div><h3>Objective</h3><div>Intraoperative Floppy Iris Syndrome (IFIS) is an intraoperative event observed during cataract surgery, characterized by iris billowing, progressive miosis, and iris prolapse. While prior studies have focused on male patients and α-adrenergic antagonists, risk factors for IFIS in females remain unclear. This study aimed to identify independent risk factors for IFIS in female cataract patients.</div></div><div><h3>Methods</h3><div>Female patients undergoing cataract surgery at Shanghai General Hospital from 2022 to 2024 were included. A total of 298 patients were enrolled in a cross-sectional study, and 416 in a cohort study. IFIS was assessed via surgical video, and logistic regression was used to identify risk factors, which were validated in the cohort.</div></div><div><h3>Results</h3><div>In the cross-sectional analysis, diabetes mellitus (DM) (OR=14.471, 95% CI: 2.183–95.929, <em>P</em>=0.006) and angiotensin II receptor blocker (ARB) use (OR=1.672, 95% CI: 1.057–26.774, <em>P</em>=0.043) were significantly associated with IFIS. In the cohort study, DM (<em>P</em>=0.023) and ARB use (<em>P</em>=0.039) remained independent risk factors.</div></div><div><h3>Conclusions</h3><div>Diabetes and ARB medication are independent risk factors for IFIS in female cataract patients. Preoperative identification of these factors may help reduce intraoperative complications and improve surgical safety.</div></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"6 2","pages":"Pages 154-158"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147798126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TOC","authors":"","doi":"10.1016/S2667-3762(26)00040-5","DOIUrl":"10.1016/S2667-3762(26)00040-5","url":null,"abstract":"","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"6 2","pages":"Pages iii-v"},"PeriodicalIF":4.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148285175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GDF11 supplementation improved retinal structure and function in retinal ischemia injury","authors":"Xuerui Zhang ,&nbsp;Yuan Yang ,&nbsp;Jiawei Yin ,&nbsp;Jie Peng ,&nbsp;Haodong Xiao ,&nbsp;Zupeng Lu ,&nbsp;Yanjun Wen ,&nbsp;Wenting Zhang ,&nbsp;Huanyu Liu ,&nbsp;Miaomiao Liu ,&nbsp;Enguang Chen ,&nbsp;Mengxiao Wu ,&nbsp;Xiang Zhang ,&nbsp;Molin Wang ,&nbsp;Yu Xu ,&nbsp;Huazhang Feng ,&nbsp;Peiquan Zhao","doi":"10.1016/j.aopr.2026.02.004","DOIUrl":"10.1016/j.aopr.2026.02.004","url":null,"abstract":"<div><h3>Background</h3><div>Retinal ischemia is a major cause of blindness and plays a detrimental role in various diseases, including occlusion of arteries or veins, diabetic retinopathy, and ocular ischemic syndrome, which could lead to the neuronal and vascular dysfunction. As a result, maintaining their activities may help to avoid visual loss. Growth differentiation factor 11 (GDF11) has been implicated that exert neuroprotective effects and promote the angiogenesis after cerebral or cardiac ischemic injury. Here, we demonstrate that GDF11 has a protective effect on ischemia retinal injury.</div></div><div><h3>Methods</h3><div>To simulate the morphological and functional results following retinal ischemia, a mouse unilateral common carotid artery occlusion (UCCAO) model was employed. Electroretinography (ERG) was conducted to assess the severity of retinal impairment. The effects were evaluated using hematoxylin and eosin (H&amp;E)-staining and immunohistochemistry. In addition, angiogenic activity affected by retinal ischemia was assessed in vivo and in vitro models.</div></div><div><h3>Results</h3><div>We successfully established the UCCAO model and expanded the pathological understanding of UCCAO-induced retinal ischemia. The treatment with GDF11 attenuated cell death, retinal edema, gliosis and apoptosis processes in the acute phase after UCCAO. In addition, GDF11 further reduced apoptosis and improved angiogenesis in the chronic phase after UCCAO. Mechanistically, GDF11 exerted its protective effects by activating the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway, underscoring its potential as a multifaceted therapeutic agent for retinal ischemia.</div></div><div><h3>Conclusions</h3><div>Our study shows the potential of GDF11 as a novel therapeutic for recovering retinal function following retinal ischemia. The results reveal that the therapeutic benefits of GDF11 are exerted during the acute and chronic phases following retinal ischemic injury.</div></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"6 2","pages":"Pages 182-191"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147952215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety thresholds for removing and preserving corneal tissue in small-incision lenticule extraction: A PRISMA-Compliant study","authors":"Huazheng Cao ,&nbsp;Junjie Ren ,&nbsp;Mohammad Alzogool ,&nbsp;Fuqi Deng ,&nbsp;Yan Wang","doi":"10.1016/j.aopr.2026.01.004","DOIUrl":"10.1016/j.aopr.2026.01.004","url":null,"abstract":"<div><h3>Background</h3><div>Ranges of corneal tissue removal and residual stroma are the most essential safety consideration for corneal refractive procedures and directly determine the eligibility of candidates who may benefit from surgery. Small-incision lenticule extraction (SMILE), a laser procedure, has been performed for more than 10 years with well-established efficacy and predictability. However, determining the optimal safety limit for corneal tissue removal is still a challenge, perplexing surgeons.</div></div><div><h3>Main text</h3><div>This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Six electronic databases (PubMed, Web of Science, Cochrane Library, Embase, China National Knowledge Infrastructure, and Wanfang Data) were searched. Corneal removal and remaining thresholds were mainly quantified by maximum lenticule thickness (MLT), residual stromal thickness (RST), and percentage of tissue alteration (PTA_SMILE, the ratio of MLT to preoperative central corneal thickness (CCT)). Thin corneas (&lt;500 μm) and eyes with extremely high myopia (&gt;-9 D) were regarded as two special conditions for independent analysis.</div></div><div><h3>Results</h3><div>Twenty-five studies (3247 eyes) were included. Corneal stability post-SMILE declined with increased tissue removal and decreased residual stroma. From a corneal biomechanical perspective, postoperative weakening of corneal biomechanical strength was more pronounced when RST was &lt;280 μm or PTA_SMILE was &gt;28%, as demonstrated by various measurements including deformation amplitude ratio, corneal hysteresis, and corneal resistance factor. Regarding posterior corneal elevation, thresholds of MLT and PTA_SMILE to prevent forward shifts following SMILE were 140–145 μm and 27%–28%, respectively. In meta-analysis, the safety index in thin corneas and extremely high myopia were 1.07 (95% CI: 0.98–1.15) and 1.17 (95% CI: 1.12–1.21), respectively. For thin corneas, the stiffness parameter at first applanation (SP-A1) exhibited less reduction compared to normal corneas after equal tissue removal, indicating biomechanical safety with minimal stiffness alteration.</div></div><div><h3>Conclusions</h3><div>Until more specific metrics are validated, RST (280 μm) and PTA_SMILE (28%) may serve as benchmarks for establishing safety thresholds for corneal tissue removal and residual stroma in SMILE. Biomechanical assessments, like SP-A1, may be promising indicators, while the preoperative CCT has limited association with postoperative morphological and biomechanical stability.</div></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"6 2","pages":"Pages 170-181"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147952218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated proteomic and metabolomic profiling reveals molecular signatures in cataract patients","authors":"Silong Chen ,&nbsp;Jiarui Guo ,&nbsp;Jie Rong ,&nbsp;Qiuli Fu ,&nbsp;Ke Yao ,&nbsp;Zhemin Zhou ,&nbsp;Yibo Yu","doi":"10.1016/j.aopr.2026.01.002","DOIUrl":"10.1016/j.aopr.2026.01.002","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to characterize systemic molecular signatures in the serum of patients with age-related cataracts and explore specific variations through integrated proteomic and metabolomic profiling.</div></div><div><h3>Methods</h3><div>Serum samples from 17 cataract patients and 24 healthy controls were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) for proteomic and metabolomic profiling. Differentially expressed proteins (DEPs) and metabolites (DEMs) were identified using multivariate statistics. Functional enrichment and multi-omics integration analyses were performed to identify key biological pathways. Key proteins were validated via enzyme-linked immunosorbent assay (ELISA) in an independent cohort (n=136).</div></div><div><h3>Results</h3><div>We identified 257 DEPs and 51 significant DEMs in cataract patients. Downregulated proteins included peroxiredoxin 6 (PRDX6), biliverdin reductase B (BLVRB), glycolytic enzyme phosphoglycerate kinase 1 (PGK1), and chaperone peptidylprolyl isomerase A (PPIA), while oxidative stress-related metabolites were elevated. Age-stratified analysis showed distinct profiles in younger patients (45–55 years). Multi-omics integration demonstrated strong correlation between proteome and metabolome, with co-enrichment in pathways such as prolactin signaling and diabetic cardiomyopathy. ELISA validation confirmed decreased levels of PGK1 and PPIA in an independent cohort.</div></div><div><h3>Conclusion<em>s</em></h3><div>Our findings reveal systemic molecular alterations in age-related cataracts, highlighting oxidative stress and metabolic dysregulation with age-specific patterns. These results provide insights into cataract pathogenesis and potential biomarkers for personalized risk assessment.</div></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"6 2","pages":"Pages 192-202"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148001226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between red blood cell distribution width to albumin ratio (RAR) and cataract risk: A cross-sectional study from NHANES 1999–2008","authors":"Renfang Zhang ,&nbsp;Fuyao Chen ,&nbsp;Yuxin Huang ,&nbsp;Xingchao Shentu","doi":"10.1016/j.aopr.2025.11.007","DOIUrl":"10.1016/j.aopr.2025.11.007","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the association between red blood cell distribution width to albumin ratio (RAR) and cataract risk among US adults.</div></div><div><h3>Methods</h3><div>A cross-sectional study was conducted utilizing the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2008. RAR was calculated using red blood cell distribution width and serum albumin measurements obtained from mobile examination centers, with higher values indicating greater systemic inflammation and nutritional deficiency. Self-reported history of cataract surgery served as a proxy for cataract diagnosis. Covariates included sociodemographic factors, lifestyle variables, and comorbidities. Multivariable logistic regression models were employed to evaluate the association between RAR and cataract. Restricted cubic spline (RCS) analysis was performed to examine potential nonlinear relationships. Propensity score matching (PSM) was implemented to reduce confounding bias. Finally, subgroup analysis was performed to investigate potential interaction effects.</div></div><div><h3>Results</h3><div>The analytical cohort comprised 26397 participants, among whom 2295 (8.70%) had cataract. Cataract patients exhibited significantly higher RAR values (3.22 ± 0.47) compared to non-cataract participants (3.06 ± 0.46). After adjustment for all covariates, a positive association between RAR and cataract was observed, both when RAR was treated as a continuous variable (odds ratio (OR)=1.412, 95% confidence interval (CI): 1.208–1.649; <em>P</em> &lt;0.001) and when analyzed categorically by quartiles. Participants in the highest RAR quartile had significantly increased cataract risk relative to the lowest quartile (OR=1.572, 95% CI: 1.261–1.958; <em>P</em> &lt;0.001). RCS analysis revealed no evidence of nonlinearity (<em>P</em> for nonlinearity =0.520). This positive association persisted in a 1:2 PSM analysis. Subgroup analysis revealed no significant interaction effects across covariates, with the RAR–cataract association remaining statistically significant in most subgroups.</div></div><div><h3>Conclusions</h3><div>Elevated RAR is independently associated with higher cataract prevalence, implicating systemic inflammation and nutritional deficiency as modifiable risk factors.</div></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"6 2","pages":"Pages 146-153"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147798128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic inference of the etiological crosstalk between primary glaucomas and retinal vascular occlusions","authors":"Chuchu Wang ,&nbsp;Tianyi Zhou ,&nbsp;Yi Yu ,&nbsp;Kaixuan Tang ,&nbsp;Xinyi Luo ,&nbsp;Wenming Shi ,&nbsp;Xiaotong Yu ,&nbsp;Jianfeng Luo ,&nbsp;Yuchen Cai ,&nbsp;Xinmin Lu ,&nbsp;Yifan Zhou","doi":"10.1016/j.aopr.2026.01.005","DOIUrl":"10.1016/j.aopr.2026.01.005","url":null,"abstract":"<div><h3>Purposes</h3><div>The etiological connection between types of primary glaucoma and the risk of retinal vascular occlusions remains elusive. We conducted a two-sample bidirectional Mendelian Randomization (MR) study with mediation analysis to elucidate causal genetic relationships and investigate potential mediating pathways.</div></div><div><h3>Methods</h3><div>Genetic instruments of primary glaucomas and retinal vascular occlusions were derived from the UK Biobank and the Finngen, respectively. A two-sample MR and reverse MR were conducted to elucidate directional and causal relationships. Ocular and systemic risk factors, including glaucomatous endophenotypes, retinal vasculature indexes, diabetes, hypertension, blood pressure (BP), cardiovascular diseases, and stroke, were also obtained from independent genome-wide association studies (GWAS) studies to investigate the mediating effects. Inverse variance weighting (IVW) was the primary analytical tool used to identify causality, and the results were verified through comprehensive and sensitivity tests for pleiotropy, heterogeneity, and stability.</div></div><div><h3>Results</h3><div>Genetically predicted primary open-angle glaucoma (POAG) may elevate retinal vein occlusion (RVO, central or branch) risk (odds ratio (OR)=1.103, 95% confidence intervals (CI): 1.008-1.208, <em>P</em>=0.032). In the reverse direction, RVO (central or branch) was associated with an OR of 1.258 for primary angle-closure glaucoma (PACG); however, this association did not reach statistical significance (95% CI: 0.996-1.589, <em>P</em>=0.054). Mediation analysis suggested that 7.4% and 4.9% of the total effect of POAG on RVO (central or branch) risk were mediated in part through systolic and diastolic BP, respectively. These primary results remained robust through a variety of sensitivity tests.</div></div><div><h3>Conclusions</h3><div>Our findings suggest that POAG may increase the risk of RVO, and this causal effect may be mediated in part through systolic and diastolic BP.</div></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"6 2","pages":"Pages 203-210"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148001225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Itaconate derivative eye drops deploy anti-inflammatory effect in treating dry eye models","authors":"Zimeng Zhai ,&nbsp;Yiteng Lu ,&nbsp;Xujiao Zhou ,&nbsp;Xingtao Zhou ,&nbsp;Feng Zhou ,&nbsp;Jiaxu Hong","doi":"10.1016/j.aopr.2026.01.003","DOIUrl":"10.1016/j.aopr.2026.01.003","url":null,"abstract":"<div><h3>Purpose<em>s</em></h3><div>To investigate the therapeutic potential of 4-Octyl itaconate (4-OI), a derivative of the endogenous immunomodulator itaconate (ITA), as a safe and effective anti-inflammatory agent for the treatment of dry eye disease (DED).</div></div><div><h3>Methods</h3><div>In vitro cytotoxicity and anti-inflammatory effects of 4-OI were evaluated in hyperosmotic human corneal epithelial cells (HCECs). An in vivo DED model was induced in C57BL/6 mice through environmental controlled chambers. Mice with DED were treated with phosphate buffered saline (PBS), 0.05% cyclosporine A (CsA) eye drops, 4-OI eye drops, or a single 4-OI intraperitoneal injection for 14 days. Corneal epithelial defects and tear secretion were assessed. The safety and underlying molecular mechanisms of topical 4-OI were evaluated using quantitative polymerase chain reaction (qPCR), Western blotting, mRNA sequencing, TdT-mediated dUTP nick-end labeling (TUNEL) assay, and hematoxylin-eosin (H&amp;E) staining. Statistical analyses were performed using independent sample <em>t</em>-tests and one-way ANOVA, with <em>P</em>&lt;0.05 considered statistically significant.</div></div><div><h3>Results</h3><div>Treatment with 4-OI eye drops significantly reduced corneal epithelial defects in DED mice (<em>P</em>&lt;0.0001) compared to the DED control group. Tear secretion was also elevated in the 4-OI eye drop-treated groups. mRNA sequencing revealed significant downregulation of inflammatory pathways, including interleukin (IL)-1 receptor activity, tumor necrosis factor (TNF) signaling, and IL-17 signaling, in the 2 mM 4-OI eye drop group. Molecular assays confirmed a marked reduction in the mRNA and protein expression of IL-1β, IL-17A, TNF-α, and <em>NFKBIZ</em> (IκBζ) in the corneas of 4-OI-treated mice. No significant corneal epithelial apoptosis or systemic toxicity was observed in the 4-OI-treated groups.</div></div><div><h3>Conclusions</h3><div>The ITA derivative 4-OI demonstrates potential as a safe and effective therapeutic option for alleviating DED by suppressing ocular inflammation through the downregulation of IL-1, IL-17, and TNF signaling pathways.</div></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"6 2","pages":"Pages 159-169"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147798182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances and challenges of CRISPR/Cas gene editing for corneal diseases","authors":"Yuqi Han ,&nbsp;Ruoqi Chen ,&nbsp;Xingchao Shentu","doi":"10.1016/j.aopr.2025.11.002","DOIUrl":"10.1016/j.aopr.2025.11.002","url":null,"abstract":"<div><h3>Background</h3><div>Corneal diseases are a major cause of global visual impairment, and current treatments remain inadequate for severe or refractory cases. The CRISPR/Cas system offers robust and precise gene-editing capabilities, yet its therapeutic potential for corneal disorders remains largely unexplored.</div></div><div><h3>Main text</h3><div>This narrative review introduces the CRISPR/Cas system and summarizes its recent advances in treating various corneal diseases, including inherited corneal dystrophies, infectious keratitis, corneal injury, and pathological neovascularization. We outline emerging preclinical and clinical studies, and analyze key issues that should be addressed for translation, including administration strategies, vector platform optimization and the mitigation of off-target toxicity.</div></div><div><h3>Conclusions</h3><div>This review provides a comprehensive and integrated overview of the current translational directions and challenges of CRISPR/Cas technology in corneal diseases from a novel perspective. It offers valuable guidance for future research and may accelerate the development of gene-editing therapies toward clinical application.</div></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"6 1","pages":"Pages 68-79"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146078129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of ultrasound cycloplasty as the first treatment in glaucoma for eyes with functional vision: A 1-year prospective study","authors":"Dingqiao Wang ,&nbsp;Zhihong Huang ,&nbsp;Yanlin Li ,&nbsp;Shaoyang Zheng ,&nbsp;Ni Guo ,&nbsp;Huanyang Shi ,&nbsp;Lin Jin ,&nbsp;Yixiu Lin ,&nbsp;Jian Ge ,&nbsp;Mingkai Lin ,&nbsp;Chengguo Zuo","doi":"10.1016/j.aopr.2025.10.001","DOIUrl":"10.1016/j.aopr.2025.10.001","url":null,"abstract":"<div><h3>Objective</h3><div>Ultrasound cycloplasty (UCP) is a non-invasive treatment traditionally used for advanced glaucoma. However, its potential as the first surgical option for moderate glaucoma with functional vision has not been thoroughly investigated. This study aimed to assess the effectiveness and safety of UCP as the initial surgery for glaucoma with residual visual function.</div></div><div><h3>Methods</h3><div>This prospective study included 117 glaucoma patients (63 males, 54 females; mean age 48.3 ​± ​17.2 years) with various glaucoma subtypes and best-corrected visual acuity (BCVA) better than 1.30 logMAR who underwent UCP as their first treatment. The primary outcomes were the surgical success rates at 12 months for both qualified and complete success. Qualified success was defined as a ≥20% reduction in intraocular pressure (IOP) from baseline, IOP between 6 and 21 mmHg, and no additional glaucoma surgery, achieved with or without anti-glaucoma medication. Complete success was defined by the same criteria, but achieved without any anti-glaucoma medications. Secondary outcomes included mean IOP, BCVA, and postoperative complications.</div></div><div><h3>Results</h3><div>The qualified success rate of UCP as the first treatment was 71.8% at 12 months, with a complete success rate (medication-free) of 27.4%. Subgroup analysis revealed that PACG had the highest qualified success rate (84.8%), followed by POAG (73.0%) and NVG (66.7%). Patients with ≤0.30 logMAR achieved the highest rate (80.0%), followed by those with 0.30-0.50 logMAR (75.0%), 0.50-1.00 logMAR (66.7%), and 1.00-1.30 logMAR (63.6%). The overall mean BCVA showed minimal change from 0.62 ​± ​0.42 logMAR at baseline to 0.63 ​± ​0.43 logMAR at 1 year. Patients experienced initial visual acuity decline in the early postoperative period, which gradually recovered after 1 week. Only 2.6% (3/117) of patients experienced a clinically significant visual decline of more than 2 lines at 12-month follow-up. No severe complications were observed.</div></div><div><h3>Conclusions</h3><div>UCP can be an effective and safe option as the first surgical treatment for glaucoma patients with visual function. UCP significantly reduces IOP over 12 months without causing significant visual acuity decline or severe complications.</div></div>","PeriodicalId":72103,"journal":{"name":"Advances in ophthalmology practice and research","volume":"6 1","pages":"Pages 1-7"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}